• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

9.680 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 611
Open 9.680
Bid (Size) 9.400 (100)
Ask (Size) 9.870 (400)
Prev. Close 9.680
Today's Range 9.680 - 9.680
52wk Range 1.995 - 15.10
Shares Outstanding 33,577,873
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study ↗
October 04, 2026
Immix Biopharma (NASDAQ:IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a... 
Via MarketBeat
News headline image
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
September 30, 2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – 
From Immix Biopharma, Inc.
Via GlobeNewswire

Performance

52-Week Range 35.9% below 52-week high
9.680
1.9952W Low 15.1052W High
1 Week 18.3% below 1-week high
9.481W Low 11.851W High

Immix Biopharma, Inc. - Common Stock (IMMX) traded between $1.99 and $15.10 over the past 52 weeks and last traded at $9.68, 35.9% below its 52-week high. Over the past week it ranged between $9.48 and $11.85.

Past 12 Months
-15.6%
-30.4%
-7.4%
+12.7%
+78.3%
+331.2%
1W -$1.79
1M -$4.23
3M -$0.77
6M +$1.09
YTD +$4.25
1Y +$7.43

IMMX was +331.2% over the past year, +12.7% over six months, +78.3% year to date, -15.6% in the last week.

12 Months vs Market
IMMX
+331.2%
DIA
+9.5%
SPY
+14.6%
QQQ
+23.3%
IWM
+14.1%

Over the past 12 months IMMX returned +331.2% versus DIA (Dow) +9.5%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +23.3% and IWM (Russell 2000) +14.1%.

Volume & Liquidity 0.00× 3-mo avg
Today 611 3-mo avg 1.7M
1W
2.7M
1M
1.8M
3M
1.7M
6M
1.6M
YTD
1.3M
1Y
1.2M

IMMX most recently traded 611 shares against a 3-month average daily volume of 1.7M.

More News

Read More
News headline image
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
September 29, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory
September 29, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
August 11, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
August 06, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
August 04, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 04, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
July 20, 2026
From Holzer & Holzer
Via GlobeNewswire
News headline image
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
May 22, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
May 21, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
May 21, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
April 09, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
March 30, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in Upcoming Investor Conferences
March 03, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
January 28, 2026
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities ↗
January 12, 2026
Via Benzinga
News headline image
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗
December 08, 2025
Via Stocktwits
Topics ETFs Economy Government
News headline image
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 07, 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 07, 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
November 12, 2025
Via Benzinga
News headline image
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
November 12, 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
November 07, 2025
Via Benzinga
News headline image
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
November 03, 2025
From Immix Biopharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Immix Biopharma, Inc. - Common Stock publicly traded?
Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Immix Biopharma, Inc. - Common Stock trade on?
Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?
The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market
What is the current price of Immix Biopharma, Inc. - Common Stock?
The current price of Immix Biopharma, Inc. - Common Stock is 9.680
When was Immix Biopharma, Inc. - Common Stock last traded?
The last trade of Immix Biopharma, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Immix Biopharma, Inc. - Common Stock?
The market capitalization of Immix Biopharma, Inc. - Common Stock is 325.03M
How many shares of Immix Biopharma, Inc. - Common Stock are outstanding?
Immix Biopharma, Inc. - Common Stock has 325M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap